Surf Air Mobility
DevvStream

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.

Moderna to Present at Upcoming Conferences in November 2023

CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

  • 2023 UBS Global Biopharma Conference on November 9th at 8:00 a.m. ET.
  • 2023 Jefferies London Healthcare Conference on November 16th at 8:30 a.m. GMT.
  • 35th Annual Piper Sandler Healthcare Conference on November 30th at 12:30 p.m. ET.

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past nine years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
This email address is being protected from spambots. You need JavaScript enabled to view it.

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.
DevvStream

DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...

CLICK TO LEARN MORE
Graphite One

Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS